An <i>In Vitro</i> Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies
Vidhisha V. Sonawane, Mike Marvin Ruth, Lian J. Pennings, Elin M. Svensson, Heiman Wertheim, Wouter Hoefsloot, Jakko van Ingen
Antimicrobial Agents and Chemotherapy · 2021-05
Abstract
For Mycobacterium avium complex pulmonary disease (MAC-PD), current treatment regimens yield low cure rates. To obtain an evidence-based combination therapy, we assessed the in vitro activity of six drugs, namely, clarithromycin (CLR), rifampin (RIF), ethambutol (EMB), amikacin (AMK), clofazimine (CLO), and minocycline (MIN), alone and in combination, against Mycobacterium avium and studied the contributions of individual antibiotics to efficacy.
MeSH terms
- Clofazimine
- Ethambutol
- Medicine
- Antibiotics
- Moxifloxacin
- Regimen
- Antimicrobial
- Pharmacology
- Microbiology
- Amikacin
- Mycobacterium avium-intracellulare infection
- Minocycline
- Clarithromycin
- Mycobacterium
- Internal medicine